| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | Entrez:55507 MIM:607437 HGNC:HGNC:13310 Ensembl:ENSG00000111291 AllianceGenome:HGNC:13310 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | G protein-coupled receptor class C group 5 member D | |||||
| GTO ID | GTC3819 |
| Trial ID | NCT06333509 |
| Disease | Multiple Myeloma | Primary Plasma Cell Leukemia |
| Altered gene | GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CT071 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed/Refractory Multiple Myeloma (RRMM) or Relapsed/Refractory Primary Plasma Cell Leukemia (RRpPCL) |
| Year | 2024 |
| Country | China |
| Company sponsor | CARsgen Therapeutics Co., Ltd. |
| Other ID(s) | CT071-HM-01 |
| Cohort 1 | |||||||||||
|
|||||||||||